ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock News
NASDAQ:ARQT - Nasdaq - US03969K1088 - Common Stock - Currency: USD
ARQT Latest News, Press Relases and Analysis
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
FDA has approved the supplemental New Drug Application (sNDA) for ZORYVE® foam 0.3% for the treatment of plaque psoriasis...
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
Arcutis announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on...
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
JAMA Dermatology published the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE® (roflumilast) foam 0.3% ...
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of 4.76% and 3.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: SABS
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Arcutis today reported financial results for the quarter ended March 31, 2025, and provided a business update....
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: QGEN
Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ALKS
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Arcutis Announces Chief Financial Officer Transition
WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Arcutis Announces Chief Financial Officer Transition
Why UWM Holdings Corp. (UWMC) Went Up On Wednesday?
We recently published a list of The Top 10 Performing Stocks on Wednesday. In this article, we are going to take a look at where UWM Holdings Corp. (NYSE:UWMC) stands against other top performing stocks on Wednesday. Wall Street’s three major indices finished in the green territory on Wednesday as investors continued to digest news […]
Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?
We recently published a list of The Top 10 Performing Stocks on Wednesday. In this article, we are going to take a look at where Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) stands against other top performing stocks on Wednesday. Wall Street’s three major indices finished in the green territory on Wednesday as investors continued to digest news […]
Arcutis and Padagis Agree to Stay Patent Lawsuit
Arcutis and Padagis Agree to Stay Patent Lawsuit
WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Arcutis today announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting (AAD)....
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
Arcutis today announced that it will present two posters at the 2025 AAD annual meeting which will take place in Orlando, FL, from March 7-11, 2025....
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
Arcutis Biotherapeutics Sees 400% Spike In Retail Buzz As Q4 Beat Fuels After-Hours Rally
Sales of Zoryve, Arcutis' leading dermatology drug, surged 413% year-over-year to $69.4 million, a 55% increase from the previous quarter.
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase...